Recordati Acquires EUSA Pharma for $845 Million
Recordati’s blockbuster acquisition of EUSA Pharma gives them access to a portfolio of four drugs that treat rare cancers.
Recordati acquired EUSA Pharma, a pharmaceutical company specializing in developing oncology treatments, for $845 million on Dec. 3, 2021. This acquisition grants Recordati access to EUSA’s portfolio of rare cancer treatments.
Included in the portfolio are four treatments:
- Qarziba (dinutuximab beta) is an anti-GD2 monoclonal antibody (mAb) designed for the treatment of high-risk neuroblastoma. According to a company press release, neuroblastoma is a rare form of cancer that forms as a result of immature nerve cells and predominantly affects children under the age of ten. Dinutuximab beta is currently approved in Europe and other countries
- Sylvant (siltuximab) is an anti-IL-6 mAb designed for the treatment of Idiopathic multicentric Castleman’s disease (iMCD). iMCD is a variation of Castleman’s disease, a rare lymph node cancer, that results in severe systemic symptoms. Siltuximab is the first and only approved treatment for iMCD in the United States and Europe
- Fotivda (tivozanib) is an oral small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3. It is currently approved for first-line treatment of advanced renal cell carcinoma in Europe and other countries
- Caphosol (calcium phosphate solution) is an oral solution for the treatment of oral mucositis resulting from chemo- and radiotherapy. It is currently approved in the US, EU, and other markets.
“We believe that the EUSA Pharma acquisition represents an excellent opportunity to further expand and reinforce our portfolio in a new and underserved therapeutic area, rare and niche oncology, with high potential growth products and will provide a platform for potential further future expansion in these areas,” said Andrea Recordati, chairman, Recordati, in a company press release. “This is another important step forward in delivering on our strategy to increase our presence in the rare disease segment and to fulfil our mission to improve the lives of patients, delivering innovative treatments that address serious unmet medical needs.”
Source: Recordati
